TYRA
Tyra Biosciences, Inc.
$32.47
-0.55
(-1.67%)
Mkt Cap
1.93B
Volume
292,946
52W Range
8.75-40.65
Sector
Healthcare
Beta
0.79
EPS (TTM)
-2.18
P/E Ratio
-13.06
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (119.95M) | (86.48M) | (69.13M) | (55.33M) | (26.29M) | (9.31M) | (4.06M) |
| EPS | -2.01 | -1.51 | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Free Cash Flow | (95.28M) | (70.44M) | (50.91M) | (50.84M) | (24.41M) | (8.07M) | (2.64M) |
| FCF / Share | -1.60 | -1.23 | -1.19 | -1.21 | -0.59 | -0.19 | -0.06 |
| Operating CF | (95.14M) | (69.77M) | (50.14M) | (50.28M) | (23.75M) | (7.76M) | (2.62M) |
| Total Assets | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M | 16.01M | 528,000 |
| Total Debt | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M | 142,000 | 253,000 |
| Cash & Equiv | 77.39M | 91.97M | 58.01M | 251.21M | 302.18M | 15.22M | 108,000 |
| Book Value | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M | (13.64M) | (4.74M) |
| Return on Equity | -0.46 | -0.25 | -0.34 | -0.21 | -0.09 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (39.30M) | (33.83M) | (29.87M) | (28.10M) | (28.15M) | (25.57M) | (24.02M) | (18.70M) | (18.19M) | (22.83M) | (21.15M) | (13.27M) |
| EPS | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 | -0.41 | -0.32 | -0.35 | -0.53 | -0.49 | -0.31 |
| Free Cash Flow | (32.66M) | (23.68M) | (22.42M) | (23.71M) | (25.47M) | (19.60M) | (17.95M) | (10.73M) | (22.16M) | (14.13M) | (17.23M) | (9.66M) |
| FCF / Share | -0.53 | -0.40 | -0.38 | -0.40 | -0.43 | -0.33 | -0.30 | -0.18 | -0.42 | -0.33 | -0.40 | -0.23 |
| Operating CF | (32.57M) | (23.62M) | (22.38M) | (23.68M) | (25.46M) | (19.59M) | (17.90M) | (10.26M) | (22.03M) | (13.53M) | (17.14M) | (9.62M) |
| Total Assets | 412.04M | 282.61M | 301.85M | 321.50M | 343.48M | 363.56M | 380.59M | 392.46M | 404.74M | 225.86M | 238.36M | 250.01M |
| Total Debt | 5.70M | 5.81M | 5.92M | 6.02M | 6.12M | 6.22M | 6.32M | 6.40M | 6.49M | 6.50M | 6.11M | 6.07M |
| Cash & Equiv | 84.95M | 77.39M | 61.95M | 98.49M | 100.72M | 91.97M | 103.89M | 99.49M | 254.37M | 58.01M | 215.65M | 232.41M |
| Book Value | 387.57M | 259.18M | 280.51M | 302.15M | 323.53M | 343.15M | 362.29M | 376.04M | 389.88M | 204.26M | 222.17M | 238.57M |
| Return on Equity | -0.10 | -0.13 | -0.11 | -0.09 | -0.09 | -0.07 | -0.07 | -0.05 | -0.05 | -0.11 | -0.10 | -0.06 |
TYRA News
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights